AxoGen (NASDAQ:AXGN – Free Report) had its target price hoisted by Canaccord Genuity Group from $22.00 to $26.00 in a report issued on Wednesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the medical equipment provider’s stock.
AxoGen Stock Up 3.0 %
AxoGen stock opened at $20.01 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. AxoGen has a 52-week low of $5.55 and a 52-week high of $21.00. The firm has a 50 day moving average price of $17.66 and a two-hundred day moving average price of $14.99. The firm has a market cap of $880.60 million, a price-to-earnings ratio of -62.53 and a beta of 1.00.
Institutional Trading of AxoGen
Hedge funds have recently modified their holdings of the stock. R Squared Ltd bought a new stake in shares of AxoGen in the 4th quarter valued at $30,000. US Bancorp DE bought a new stake in shares of AxoGen in the 4th quarter valued at $30,000. State of Wyoming bought a new stake in shares of AxoGen in the 4th quarter valued at $31,000. Quest Partners LLC increased its stake in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 2,076 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of AxoGen in the 4th quarter valued at $93,000. Institutional investors own 80.29% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
- Five stocks we like better than AxoGen
- Find and Profitably Trade Stocks at 52-Week Lows
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- What is the Dow Jones Industrial Average (DJIA)?
- 5 Best Gold ETFs for March to Curb Recession Fears
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.